Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch

Executive Summary

Amicus plans to file migalastat for Fabry disease in the US in the fourth quarter, after FDA gave the greenlight, reversing a decision last year to require an additional Phase III study.


Related Content

Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure
Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace
Gottlieb Becomes US FDA Commissioner With Immediate Issues Pending
Amicus Eyes Broad Future Label For Migalastat After Huge Filing Setback
Oral Fabry Drug Clears CHMP, Amicus Sets Up 'Searchable Mutation' Website
Persistence Pays Off For Amicus: Positive Migalastat Data In Hand
Going Deeper Into Rare Disease, GSK Takes Reins of Amicus Fabry Program


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts